Doralina L. Anghelescu

Doralina L. Anghelescu

Auto-generated profile, based on publicly available information

Doralina L. Anghelescu

St. Jude Children’s Research Hospital

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2016 in Pediatric Drugs
Verified
Journal Article
Closed access
PDF file
AMArthura D. Moore
Arthura D. Moore
DADoralina L. Anghelescu
Doralina L. Anghelescu

25 September 2007 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
DADoralina L. Anghelescu
Doralina L. Anghelescu
LBLaura L. Burgoyne
Laura L. Burgoyne
TLTiebin Liu
Tiebin Liu
CLChin‐Shang Li
Chin‐Shang Li
CPChing‐Hon Pui
Ching‐Hon Pui
JSJohn T. Sandlund
John T. Sandlund

11 February 2011 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
DADoralina L. Anghelescu
Doralina L. Anghelescu
LFLane G. Faughnan
Lane G. Faughnan
SJSima Jeha
Sima Jeha
MRMary V. Relling
Mary V. Relling
PHPamela S. Hinds
Pamela S. Hinds
CPChing‐Hon Pui
Ching‐Hon Pui

1 June 2008 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DADoralina L. Anghelescu
Doralina L. Anghelescu
LBLaura L. Burgoyne
Laura L. Burgoyne
WLWei Liu
Wei Liu
GHGisele M. Hankins
Gisele M. Hankins
CCCheng Cheng
Cheng Cheng
GBGeorge B. Bikhazi
George B. Bikhazi

14 August 2013 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
DADoralina L. Anghelescu
Doralina L. Anghelescu
JEJennifer Harman Ehrentraut
Jennifer Harman Ehrentraut
LFLane G. Faughnan
Lane G. Faughnan
The FDA’s 2012 risk evaluation and mitigation strategy is a major step toward systematically reducing the inherent risks of chronic opioid therapy for pain, but does not distinguish between risks related to sources of pain. This article discusses the effect of risk mitigation in the treatment of cancer pain, with a focus on pretreatment screening and ongoing monitoring in this patient population that often requires pain management at some time during cancer treatment. Experience with screening, risk stratification, and interventions at one cancer center is shared, along with some recommendations for practice. A new screening checklist is proposed that summarizes known risk factors. Patients with cancer are not protected from the problems of opioid abuse/misuse, and the multidisciplinary cancer treatment team should coordinate an evaluation of risk and the monitoring of aberrant behaviors as part of the comprehensive care plan. The FDA’s 2012 risk evaluation and mitigation strategy is a major step toward systematically reducing the inherent risks of chronic opioid therapy for pain, but does not distinguish between risks related to sources of pain. This article discusses the effect of risk mitigation in the treatment of cancer pain, with a focus on pretreatment screening and ongoing monitoring in this patient population that often requires pain management at some time during cancer treatment. Experience with screening, risk stratification, and interventions at one cancer center is shared, along with some recommendations for practice. A new screening checklist is proposed that summarizes known risk factors. Patients with cancer are not protected from the problems of opioid abuse/misuse, and the multidisciplinary cancer treatment team should coordinate an evaluation of risk and the monitoring of aberrant behaviors as part of the comprehensive care plan.

22 November 2010 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
DADoralina L. Anghelescu
Doralina L. Anghelescu
LFLane G. Faughnan
Lane G. Faughnan
JBJustin N. Baker
Justin N. Baker
JYJie Yang
Jie Yang
JKJavier R. Kane
Javier R. Kane